Earlier this year, a team of researchers from Austria found in a case -control study that women who produced more of the cytokine interleukin 10 (IL-10) due to a genetic variation or polymorphism had a lower incidence of breast cancer.
" The mechanism remains to be determined but may include antiangiogenic functions of IL-10, " said study leader Uwe Langsenlehner, M.D., of the Medical University of Graz, Austria. " If this result can be confi rmed in additional studies, determination of IL-10 genotypes may help give a more precise individual breast cancer risk profi le. " This research, published in March in Breast Cancer Research and Treatment, is one of a growing number of studies that are helping to defi ne how cytokine polymorphisms affect cancer risk, initiation, and progression.
IL-10 is one of more than 300 -400 known cytokines produced by the immune system that are mediators of immunity, infection, and infl ammation, said Joost Oppenheim, M.D., chief of molecular immunology in the Division of Basic Sciences at the National Cancer Institute. " Certain cytokines [such as tumor necrosis factor α (TNF-α ) and IL-6] may promote cancer growth and spreading, stimulate cells to survive longer, are proangiogenic, encourage infl ammation, and cause free radical damage of DNA and instability, " he said. Others, such as IL-2, granulocyte -macrophage colonystimulating factor (GM-CSF), and interferons, inhibit cancer growth and spreading by stimulating other immune cells, such as T cells and natural killer cells. Animal models show that IL-10 can have immunosuppressive activity, Oppenheim said. " Many of the cytokines such as TNF α , IL-10, IL-1, and IL-6 have multiple biological roles, based on the fact that their receptors are expressed by diverse cell populations, which may result in apparently opposing effects, " Oppenheim added.
Since the early 1990s, researchers have tested recombinant cytokines, including IL-2, GM-CSF, and interferon, as local and systemic immunotherapies for cancer, in combination with chemotherapy in gene transfer experiments, and in vaccines -with limited success. These cytokines have also been studied for their potential antitumor properties since recombinant cytokines became available in suffi cient quantities more than 20 years ago, starting with interferons and IL-2, said Oppenheim. Only in the past few years have researchers begun focusing on the role that endogenous cytokines may play in increasing cancer risk.
Langsenlehner's study adds to other research that suggests that low IL-10 levels are associated with risk for prostate, cervical, and noncardia gastric cancers, melanoma, and lymphoma. However, the role of IL-10 in cancer remains ambiguous; other studies show that high levels of IL-10 may actually be a risk factor for other cancers, in cluding cervical, cardia gastric, and ovarian cancers and myeloma. " The dual biological function of IL-10 as an anti-infl ammatory (potentially cancer-promoting) and antiangiogenic (potentially cancer-inhibiting) agent refl ects the apparently confl icting data, " Langsenlehner noted.
Many other cytokine polymorphisms are being studied for their relationship to cancer risk. High levels of the proinfl ammatory cytokine IL-1 β may be associated with an increased risk of gastric cancer, and high levels of IL-6 may be associated with an increased risk of youngadult Hodgkin lymphoma. Whether any of these associations are causal, however, is an open question. High levels of certain cytokines have also been found in the blood of patients with certain cancers and may be associated with poor prognoses, but again, rigorous studies to establish the true nature of the relationship haven't been done. Also, in established cancers, expression of particular cytokines is likely to be different from that in normal patients.
Cytokines in the Microenvironment
From her studies of cytokines, Frances Balkwill, Ph.D., professor of cancer biology at Cancer Research U.K.'s Translational Research Laboratory in London, concluded that certain cytokines are actually cancer-modifying genes. In human ovarian cancer, she found that the cytokine network is rich in proinfl ammatory cytokines, growth factors, and chemokines and that TNF-α in particular plays a central role in the microenvironment -in stromal development and regulation of matrix metalloproteinases required for tissue invasion.
Just as using TNF-α -blocking monoclonal antibodies to treat rheumatoid arthritis has had some success, so Balkwill believes they could work with other agents to treat cancer. There are more than a dozen trials under way now in a range of cancers with TNF-α -blocking antibodies, she noted. Oppenheim said that although he had doubts this approach would be effective in cancer, he hadn't believed that they would work in arthritis, either. " I could be wrong again, " he said.
Blocking certain cytokines such as TNF-α and IL-10 is not simple, as they each have multiple immunomodulatory effects. Not all cytokines have just one role, either; some, such as IL-10 and TNF-α , may have tumor-promoting or -inhibiting effects at different concentrations and in different environments. Oppenheim called this the " ying-yang effect " of cytokines. Balkwill agrees. " It's a question of balance: A lot can kill a tumor, a little may have the opposite effect, and vice versa, " Balkwill said.
" In the context of breast cancer risk, IL-10 may act as a double-edged sword: On the one hand, high levels could facilitate development of cancer by supporting tumor escape from the immune response (a known effect), and on the other hand, IL-10's antiangiogenic effects could prevent or reduce tumor growth and metastasis, " Langsenlehner said. " It may depend on the biology of each cancer and the microenvironment whether the anti-infl ammatory mechanism -tumor escape -of IL-10 is stronger than the antiangiogenic effect, or the reverse, " he said.
Cytokines and the effect of cytokine polymorphisms on the development and progression of cancer cannot be considered in isolation because of complex interactions between them, according to Langsenlehner. For example, TNF-α is downregulated by IL-10 and by the crosstalk of many other cytokines. " This also makes it diffi cult to establish the precise mechanism of IL-10 action, " Langsenlehner said.
Other studies indicate that IL-10 can indirectly inhibit proinfl ammatory cytokine production by both T and natural killer cells, and suppress antitumor responses.
Pathogen Connection?
It is well known that infection with Helicobacter pylori or some human papillomaviruses can cause gastric cancer or cervical cancer, respectively, but why one infected person progresses to cancer and another does not is not yet understood. One contributing factor could be an individual's genetic cytokine profi le. In a recent review, Glenn Dranoff, M.D., of the Dana-Farber Cancer Institute in Boston, pointed out that pathogens can stimulate chronic cytokine expression, which in turn can create chronic infl ammation, which can set off a cascade of cytokines that pushes chronic infection toward cellular transformations that lead to cancer in some individuals. Individual cytokine profi les could be the missing link between infection and cancer in some people.
For example, one study of 146 Zimbabwean women found that patients with cervical cancer were more likely than those without the disease to carry a polymorphism for enhanced IL-10 production. No women in the healthy study arm were high-producers of IL-10. Some researchers have hypothesized that higher levels of IL-10 promote HPV growth, viral replication, and malignant transformation of infected cells in women infected with the virus -a possible explanation of why some women with HPV get cervical cancer while others do not. Again, since cytokines do not work in isolation, it will be important to study the relationship of IL-10 to other cytokines in cervical cancer patients.
The research of Emad El-Omar, M.D., of the University of Aberdeen's Department of Medicine and Therapeutics in Scotland, illustrates how host genetic profi les affect the development of gastric cancer. " Being a gastroenterologist, I thought that cytokine levels of proinfl ammatory cytokines might help explain why one patient with high acid production and H. pylori infection gets gastric cancer but another develops an ulcer, " he said. Half the world is infected with H. pylori , but relatively few get gastric cancer; genetics -cytokine polymorphisms -may help explain individual risk.
In one study, he found that a highproducing proinfl ammatory cytokine polymorphism genotype of IL-1 β increased the risk of one type of gastric cancer by producing low-acid secretion in the presence of H. pylori infection. He later identifi ed four proinfl ammatory polymorphisms of three additional genes (IL-1 receptor antagonist, IL-10, and TNF-α ) and found that each further increased the risk of gastric tumors; individuals with two of the genes had more risk than those with one, and those with all four proinfl ammatory genotypes had the highest risk of gastric cancer. " The association of these polymorphisms with gastric cancer requires the presence of H. pylori and may be most important early in the disease process, " he said.
" Cytokine gene polymorphisms represent one component of a complex interplay among the host, pathogen, and environmental factors involved in
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Downloaded from https://academic.oup.com/jnci/article-abstract/97/16/1175/2521368 by guest on 22 November 2018 gastric carcinogenesis, " El-Omar added. The risk of gastric cancer is greatest in those with both bacterial and high-risk host genotypes, he found. " Some dismiss the possibility that cytokine polymorphisms impact cancer risk, " said El-Omar. But he and a growing number of researchers believe that they can help explain why certain individuals are at greater risk of sporadic cancers than others with seemingly similar risk factors. Rather than a strict genetic mutation view of cancer, cytokine polymorphisms, together with environmental factors and epigenetic changes due to environmental factors, can help explain cancer risk, said Oppenheim.
It may be more diffi cult to ascertain a causal connection between cancer and cytokine polymorphisms such as TNF-α and IL-10 because of their dual biological functions. " It depends on the biology of each cancer and its microenvironment -whether the anti-infl ammatory, or tumor escape, mechanism of IL-10 or the antiangiogenic, antiproliferative effect is stronger, " said Langsenlehner.
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